Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era-Reference-Cited by-同舟云学术

Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era

Published:2024-07 Issue:7 Volume:54 Page:1223-1227
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Baggio Diva¹²^ORCID,Chung Eliza²,Wellard Cameron²,Waters Neil²,Cushion Tania¹,Chong Geoffrey³,Cochrane Tara⁴^ORCID,Cull Gavin⁵,Giri Pratyush⁶,Hamad Nada⁷^ORCID,Johnston Anna⁸⁹,Lee Denise¹⁰,Murali Aarya¹¹,Morgan Susan¹²,Mulligan Stephen¹³,Talaulikar Dipti¹⁴^ORCID,Ratnasingam Sumita¹⁵,Wood Erica²^ORCID,Hawkes Eliza¹^ORCID,Opat Stephen¹⁶

Affiliation:

1. Olivia Newton‐John Cancer Research and Wellness Centre, Austin Health Melbourne Victoria Australia

2. Monash University Melbourne Victoria Australia

3. Ballarat Regional Integrated Cancer Centre Ballarat Victoria Australia

4. Gold Coast University Hospital Gold Coast Queensland Australia

5. Sir Charles Gairdner Hospital Perth Western Australia Australia

6. Royal Adelaide Hospital Adelaide South Australia Australia

7. St Vincent's Health Sydney New South Wales Australia

8. Royal Hobart Hospital Hobart Tasmania Australia

9. University of Tasmania Hobart Tasmania Australia

10. Eastern Health Melbourne Victoria Australia

11. Princess Alexandra Hospital Brisbane Queensland Australia

12. Alfred Hospital Melbourne Victoria Australia

13. Royal North Shore Hospital Sydney New South Wales Australia

14. Canberra Health Services, Australian National University Canberra Australian Capital Territory Australia

15. Barwon Health, University Hospital Geelong Victoria Australia

16. Monash Health Melbourne Victoria Australia

Abstract

AbstractPopulation‐based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age‐standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow‐up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.

Funder

Janssen Pharmaceutica

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16445

Reference20 articles.

1. SwerdlowS CampoE HarrisN JaffeE PileriS SteinH et al.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues [Internet]. Geneva: WHO Press; 2008. Available from URL:http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=70&codcch=4002.

2. Perturbation of the normal immune system in patients with CLL

3. Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome

4. Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study

5. National Comprehensive Cancer Network Inc.NCCN Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Internet]; 2023 [cited 2023 Jun 13]. Available from URL:https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478.